Friday, October 2, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 20, 2026

Taxes are going to change for retirees under Trump’s ‘big beautiful bill’. Here’s why you can’t afford to waste time

View original at finance.yahoo.com
Taxes are going to change for retirees under Trump’s ‘big beautiful bill’. Here’s why you can’t afford to waste time Samuel Corum/Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Over 90% of Americans who shopped around and compared auto insurance rates from multiple lenders managed to save by switching carriers

    80% confidence
  • One asset will surge 400% in a year

    80% confidence
  • A 7-step plan works every single time to kill debt, get rich in America, and anyone can do it

    80% confidence
  • 8 repeatable money rules were used to turn $9,800 into a $150B fortune, and these rules work for anyone

    80% confidence
  • Nearly 50% of Americans are making 1 big Social Security mistake

    80% confidence
  • The OBBBA includes a $1.1 trillion cut on federal spending for the Affordable Care Act and Medicaid across the next decade

    80% confidence
  • Nearly one in eight Americans rely on SNAP benefits

    80% confidence
  • 53% of American adults strongly or somewhat oppose Trump's budget

    80% confidence
  • An estimated 11.8 million people will lose health coverage by 2034 due to OBBBA cuts, revised eligibility requirements, additional charges and new limitations

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com